Additionally, the recombinant human granulocyte colony-stimulating factor (rhG-CSF) could reduce the occurrence of CARDS.336 However, rhG-CSF fails to alleviate the severity in patients with COVID-19, and the underlying therapeutic effects and potential mechanisms remain ambiguous in CARDS. This evidence concerns the gene CSF2 and COVID-19.